Literature DB >> 12371122

Bone and joint infections in injection drug users.

Vivek Kak1, Pranatharthi H Chandrasekar.   

Abstract

Skeletal infections in injection drug users have an insidious onset, present with indolent symptoms, and often occur in unusual locations. Unless physicians are familiar with the disease entities unique to the injection drug user, the diagnosis is frequently delayed. Systemic signs of infection are often lacking. The organisms causing the infection represent a wide spectrum; hence, empiric therapy is not generally recommended. Plain-film radiographs are of little help for early diagnosis. Imaging studies, especially radionucleotide studies and CT or MR imaging scans, can help localize the site of infection. For etiologic diagnosis of these infections, bone biopsy or needle aspiration of the involved bone or joint is required. The choice of antibiotic agent should be based on culture results and the antimicrobial susceptibility of the causative organism. Treatment may also involve surgical drainage or débridement of affected structures. Failure to manage acute bone and joint infection aggressively inevitably leads to chronic, often incurable, infection. Successful therapy requires a team approach including the internist and consultants from orthopedic surgery, infectious diseases, and substance abuse counselors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12371122     DOI: 10.1016/s0891-5520(02)00016-8

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  24 in total

1.  Microbiology of bone and joint infections in injecting drug abusers.

Authors:  Daniel C Allison; Paul D Holtom; Michael J Patzakis; Charalampos G Zalavras
Journal:  Clin Orthop Relat Res       Date:  2010-08       Impact factor: 4.176

2.  Risk practices associated with bacterial infections among injection drug users in Denver, Colorado.

Authors:  Kristina T Phillips; Michael D Stein
Journal:  Am J Drug Alcohol Abuse       Date:  2010-03       Impact factor: 3.829

3.  Bone and joint infection.

Authors:  Julia Colston; Bridget Atkins
Journal:  Clin Med (Lond)       Date:  2018-03       Impact factor: 2.659

4.  Skin and needle hygiene intervention for injection drug users: results from a randomized, controlled Stage I pilot trial.

Authors:  Kristina T Phillips; Michael D Stein; Bradley J Anderson; Karen F Corsi
Journal:  J Subst Abuse Treat       Date:  2012-02-14

Review 5.  Mechanisms of Immune Evasion and Bone Tissue Colonization That Make Staphylococcus aureus the Primary Pathogen in Osteomyelitis.

Authors:  Gowrishankar Muthukrishnan; Elysia A Masters; John L Daiss; Edward M Schwarz
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

Review 6.  Reframing "prevention with positives": incorporating counseling techniques that improve the health of HIV-positive patients.

Authors:  Barbara Gerbert; Dale W Danley; Karen Herzig; Kathleen Clanon; Daniel Ciccarone; Paul Gilbert; Michael Allerton
Journal:  AIDS Patient Care STDS       Date:  2006-01       Impact factor: 5.078

7.  [Injection site abscesses in intravenous drug users. Frequency of associated complications related to localisation].

Authors:  U Pfefferkorn; C T Viehl; S Bassetti; T Wolff; D Oertli
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

8.  Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: a cohort study.

Authors:  Elisa Lloyd-Smith; Evan Wood; Ruth Zhang; Mark W Tyndall; Sam Sheps; Julio S G Montaner; Thomas Kerr
Journal:  BMC Public Health       Date:  2010-06-09       Impact factor: 3.295

9.  [Bacterial osteitis. Special considerations in immunocompromised patients].

Authors:  C Niedhart; O Miltner; K-W Zilkens; F U Niethard
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

Review 10.  Musculoskeletal Infections in the Emergency Department.

Authors:  Daniel C Kolinsky; Stephen Y Liang
Journal:  Emerg Med Clin North Am       Date:  2018-09-06       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.